單株抗體治療市場規模、佔有率、成長分析、按生產、按來源、按治療方法、按管理、按最終用戶、按地區 - 行業預測，2025-2032

2023年單株抗體治療市場規模為1,540.5億美元，從2024年的1,653億美元成長到2032年的2,904.4億美元，複合年成長率預計為7.3%。

全球單株抗體治療市場正在強勁成長，主要是由於癌症、自體免疫疾病和心血管疾病等慢性病盛行率上升所推動。單株抗體在治療這些疾病方面的有效性極大地鼓勵了它們的採用。此外，人口老化和文明病的增加正在刺激市場擴張。技術進步正在增強生產高度特異性抗體的能力並改善治療結果。此外，對個人化醫療和標靶治療的日益重視正在推動對單株抗體療法的需求，預計該市場在未來幾年將持續成長。總體而言，這些趨勢顯示單株抗體在醫療保健領域的前景。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析

單株抗體治療市場規模：依產量分類

• 市場概況
• In vitro
• In vivo

單株抗體治療市場規模：依來源分類

• 市場概況
• 人類
• 人性化
• 嵌合體
• 其他

單株抗體治療市場規模：依治療方法

• 市場概況
• 自體免疫疾病與發炎性疾病
• 腫瘤學
• 血液學
• 眼科
• 其他

單株抗體治療市場規模：依給藥方式分類

• 市場概況
• 靜脈
• 皮下的
• 其他

單株抗體治療市場規模：依最終用戶分類

• 市場概況
• 醫院
• 長期照護設施
• 其他
• 單株抗體治療市場規模
• 北美（生產供應處理管理最終用戶）
  • 美國
  • 加拿大
• 歐洲（生產供應處理管理最終用戶）
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區（製造供應處理管理最終用戶）
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲（生產供應處理管理最終用戶）
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲（生產供應處理管理最終用戶）
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
• 收益與前一年同期比較（2022-2024）

主要企業簡介

• Zoetis Inc.（USA）
• Merck & Co., Inc.（USA）
• Elanco Animal Health Incorporated（USA）
• Boehringer Ingelheim International GmbH（Germany）
• Ceva Sante Animale（France）
• Virbac（France）
• Vetoquinol（France）
• Bayer AG（Germany）
• Novartis AG（Switzerland）
• Eli Lilly and Company（USA）
• Sanofi（France）
• Intervet Inc.（Netherlands）
• Alltech（Ireland）
• Huvepharma（Bulgaria）
• Kemin Industries（USA）
• Novus International（USA）
• Biomin Holding GmbH（Austria）
• ADM Animal Nutrition（USA）
• Adisseo（France）
• DSM（Netherlands）

結論和建議

Monoclonal Antibody Therapy Market size was valued at USD 154.05 Billion in 2023 and is poised to grow from USD 165.3 Billion in 2024 to USD 290.44 Billion by 2032, growing at a CAGR of 7.3% during the forecast period (2025-2032).

The global monoclonal antibody therapy market is witnessing robust growth, primarily driven by the rising prevalence of chronic diseases such as cancer, autoimmune disorders, and cardiovascular conditions. The effectiveness of monoclonal antibodies in treating these illnesses is significantly boosting their adoption. Furthermore, an aging population coupled with the increase in lifestyle-related diseases is fueling market expansion. Technological advancements have enhanced the production capabilities of highly specific antibodies, thereby improving therapeutic outcomes. Additionally, the growing emphasis on personalized medicine and targeted therapies is amplifying the demand for monoclonal antibody therapies, positioning this market for sustained growth in the coming years. Overall, these trends indicate a promising future for monoclonal antibodies in the healthcare landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Monoclonal Antibody Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Monoclonal Antibody Therapy Market Segmental Analysis

Global Monoclonal Antibody Therapy Market is segmented by production, source, therapy, administration, end user and region. Based on production, the market is segmented into in vitro and in vivo. Based on source, the market is segmented into human, humanized, chimeric and other. Based on therapy, the market is segmented into autoimmune and inflammatory disorders, oncology, hematology, ophthalmology and others. Based on administration, the market is segmented into intravenous, subcutaneous and other. Based on end user, the market is segmented into hospitals, long term care facilities and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Monoclonal Antibody Therapy Market

The Monoclonal Antibody Therapy market is primarily driven by notable advancements in biotechnology and genetic engineering. These developments have been crucial in creating sophisticated monoclonal antibody therapies that exhibit enhanced specificity and efficacy while minimizing side effects. Innovative techniques, including genetic manipulation, enable researchers to tailor antibodies for particular targets, thereby maximizing their therapeutic effectiveness. As a result, these scientific breakthroughs have expanded the applications of monoclonal antibody therapies and significantly improved their success rates in treating various diseases. This continued evolution in biotechnology is essential for the growth and evolution of the monoclonal antibody therapy market.

Restraints in the Monoclonal Antibody Therapy Market

The Monoclonal Antibody Therapy market faces several constraints primarily related to potential side effects and safety issues associated with these treatments. Patients may experience infusion-related reactions during administration, which can lead to discomfort and anxiety. Additionally, there is a risk of immunogenicity, where the patient's immune system reacts against the therapy itself, potentially reducing its effectiveness. Off-target effects may also occur, where the antibody interacts with unintended biological targets, leading to adverse outcomes. To mitigate these concerns, it is essential to implement rigorous safety monitoring, thorough risk assessments, and transparent communication regarding potential side effects, thereby upholding patient safety and trust in these therapies.

Market Trends of the Monoclonal Antibody Therapy Market

The monoclonal antibody therapy market is witnessing a robust trend towards increasing adoption of personalized and targeted therapies. As healthcare shifts towards individualized treatment plans, monoclonal antibodies are at the forefront of this evolution, effectively treating conditions such as cancer, autoimmune disorders, and infectious diseases. The integration of companion diagnostics, genetic profiling, and biomarker identification enhances the development and prescription of these therapies, ensuring more precise treatments that optimize therapeutic efficacy and reduce adverse effects. This growing emphasis on personalized medicine is expected to drive substantial growth in the monoclonal antibody market, reflecting a transformative approach to disease management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Monoclonal Antibody Therapy Market Size by Production & CAGR (2025-2032)

• Market Overview
• In Vitro
• In Vivo

Global Monoclonal Antibody Therapy Market Size by Source & CAGR (2025-2032)

• Market Overview
• Human
• Humanized
• Chimeric
• Other

Global Monoclonal Antibody Therapy Market Size by Therapy & CAGR (2025-2032)

• Market Overview
• Autoimmune And Inflammatory Disorders
• Oncology
• Hematology
• Ophthalmology
• Others

Global Monoclonal Antibody Therapy Market Size by Administration & CAGR (2025-2032)

• Market Overview
• Intravenous
• Subcutaneous
• Other

Global Monoclonal Antibody Therapy Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Long Term Care Facilities
• Others
• Global Monoclonal Antibody Therapy Market Size & CAGR (2025-2032)
• North America (Production, Source, Therapy, Administration, End User)
  • US
  • Canada
• Europe (Production, Source, Therapy, Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Production, Source, Therapy, Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Production, Source, Therapy, Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Production, Source, Therapy, Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
• Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Zoetis Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Sante Animale (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intervet Inc. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alltech (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Huvepharma (Bulgaria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kemin Industries (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novus International (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomin Holding GmbH (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ADM Animal Nutrition (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adisseo (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DSM (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations